Mon Sep 09 14:52:00 UTC 2024: ## CorMedix Secures Major Supply Contract for Infection Prevention Drug DefenCath®
**BERKELEY HEIGHTS, NJ – September 9, 2024** – CorMedix Inc. (Nasdaq: CRMD) today announced a multi-year commercial supply agreement with a leading US healthcare provider for its FDA-approved infection prevention drug, DefenCath®. This agreement marks a significant milestone for CorMedix, as it will provide access to DefenCath for thousands of patients across the country.
The healthcare provider, which serves over 2,000 clinics nationwide, will initially target up to 4,000 patients at risk for catheter-related bloodstream infections (CRBSI). DefenCath, a combination of taurolidine and heparin, is indicated to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC).
“This agreement is a testament to the growing demand for DefenCath and its potential to improve patient outcomes,” said CorMedix CEO, Joseph Todisco. “We are committed to ensuring broad access to this important infection reduction mechanism.”
The company received FDA approval for DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) in November 2023. DefenCath was commercially launched in inpatient settings in April 2024 and became available for outpatient use in July following CMS reimbursement approval.
Shipments for DefenCath under the new agreement are expected to begin in the fourth quarter of 2024.
CorMedix Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is focused on expanding the use of DefenCath as a catheter lock solution for other patient populations.
First Piper 